Abstract
The aim of this study was to investigate the pharmacokinetics of glibenclamide (Gli) administrated orally and intravenously to normal and diabetic rats. The AUC(0–720min) of orally administered Gli in diabetic rats (321.24mgmin/L) was greater than that (57.752mgmin/L) in normal rats. CL (0.019L/min/kg) was significantly slower than that (0.092L/min/kg) of normal rats. The AUC(0–480min) of intravenous Gli in diabetic rats (1528.280mgmin/L) also was significantly greater than that (509.523mgmin/L) in normal rats, and CL was decreased approximately 3-fold. No significant difference in intestinal absorption of Gli was observed between normal and diabetic rats as determined by in situ single-pass intestinal perfusion. The clearance of Diclofenac (a substrate of CYP2C9) was determined to evaluate changes in hepatic drug-metabolizing enzyme activity in rats. The CL in diabetic rats was significantly lower (42.43% decrease) than that in normal rats. Hepatic protein expression of CYP2C9 was measured using Western blot analysis; compared with normal rats, the hepatic protein expression of CYP2A9 was decreased in diabetic rats. Therefore, the slower clearance of Gli in diabetic rats can be attributed primarily to the lower expression of hepatic CYP2C9.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
